{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T06:29:19Z","timestamp":1792132159539,"version":"4.4.0"},"reference-count":131,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007184","name":"Yale School of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007184","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T35DK104689"],"award-info":[{"award-number":["T35DK104689"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","theclinics.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Dermatologic Clinics"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.det.2024.02.001","type":"journal-article","created":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T13:26:51Z","timestamp":1710336411000},"page":"339-355","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":59,"title":["Biologics for Psoriasis"],"prefix":"10.1016","volume":"42","author":[{"given":"Anthony Mitchel","family":"Wride","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria F.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah L.","family":"Spaulding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Tkachenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey M.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"19","key":"10.1016\/j.det.2024.02.001_bib1","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.det.2024.02.001_bib2","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1056\/NEJMra0804595","article-title":"Psoriasis","volume":"361","author":"Nestle","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.det.2024.02.001_bib3","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1586\/ecp.11.28","article-title":"Pharmacodynamics of TNF-\u03b1 inhibitors in psoriasis","volume":"4","author":"Vergou","year":"2011","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.det.2024.02.001_bib4","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1365-2133.2007.07945.x","article-title":"Antitumour necrosis factor-alpha chimeric antibody (infliximab) inhibits activation of skin-homing CD4+ and CD8+ T lymphocytes and impairs dendritic cell function","volume":"157","author":"Bedini","year":"2007","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.det.2024.02.001_bib5","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/j.1365-2133.2005.07078.x","article-title":"Programmed cell death of keratinocytes in infliximab-treated plaque-type psoriasis","volume":"154","author":"Kr\u00fcger-Krasagakis","year":"2006","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.det.2024.02.001_bib6","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1124\/jpet.301.2.418","article-title":"Binding and functional comparisons of two types of tumor necrosis factor antagonists","volume":"301","author":"Scallon","year":"2002","journal-title":"J\u00a0Pharmacol Exp Ther"},{"issue":"3","key":"10.1016\/j.det.2024.02.001_bib7","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1111\/bjd.16659","article-title":"MiR-146a-5p correlates with clinical efficacy in patients with psoriasis treated with the tumour necrosis factor-alpha inhibitor adalimumab","volume":"179","author":"Mens\u00e0","year":"2018","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.det.2024.02.001_bib8","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.pharmthera.2007.10.001","article-title":"Tumor necrosis factor antagonist mechanisms of action: a comprehensive review","volume":"117","author":"Tracey","year":"2008","journal-title":"Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.det.2024.02.001_bib9","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23042366","article-title":"Pharmacogenomics of Anti-TNF Treatment Response Marks a New Era of Tailored Rheumatoid Arthritis Therapy","volume":"23","author":"Wysocki","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.det.2024.02.001_bib10","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1089\/bfm.2022.0033","article-title":"Treating Psoriasis During Breastfeeding","volume":"17","author":"Anderson","year":"2022","journal-title":"Breastfeed Med"},{"issue":"2","key":"10.1016\/j.det.2024.02.001_bib11","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1136\/annrheumdis-2017-212196","article-title":"Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study","volume":"77","author":"Mariette","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.det.2024.02.001_bib12","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1002\/ibd.20225","article-title":"Mechanism of action of certolizumab pegol (CDP870): in\u00a0vitro comparison with other anti-tumor necrosis factor alpha agents","volume":"13","author":"Nesbitt","year":"2007","journal-title":"Inflamm Bowel Dis"},{"issue":"11","key":"10.1016\/j.det.2024.02.001_bib13","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1080\/17425255.2019.1681969","article-title":"Pharmacodynamics OF TNF \u03b1 inhibitors for the treatment of psoriasis","volume":"15","author":"Campanati","year":"2019","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"2","key":"10.1016\/j.det.2024.02.001_bib14","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.cytogfr.2014.02.001","article-title":"Lymphotoxin and TNF: how it all began-a tribute to the travelers","volume":"25","author":"Ruddle","year":"2014","journal-title":"Cytokine Growth Factor Rev"},{"issue":"4","key":"10.1016\/j.det.2024.02.001_bib15","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.jaad.2004.02.021","article-title":"Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial","volume":"51","author":"Gottlieb","year":"2004","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.det.2024.02.001_bib16","doi-asserted-by":"crossref","first-page":"31.e1-15","DOI":"10.1016\/j.jaad.2006.07.017","article-title":"A\u00a0randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis","volume":"56","author":"Menter","year":"2007","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"9494","key":"10.1016\/j.det.2024.02.001_bib17","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S0140-6736(05)67566-6","article-title":"Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial","volume":"366","author":"Reich","year":"2005","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.det.2024.02.001_bib18","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/j.1365-2133.2007.08315.x","article-title":"Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION)","volume":"158","author":"Saurat","year":"2008","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.det.2024.02.001_bib19","doi-asserted-by":"crossref","first-page":"302.e6","DOI":"10.1016\/j.jaad.2018.04.012","article-title":"Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2)","volume":"79","author":"Gottlieb","year":"2018","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.det.2024.02.001_bib20","doi-asserted-by":"crossref","first-page":"266.e5","DOI":"10.1016\/j.jaad.2018.04.013","article-title":"Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT)","volume":"79","author":"Lebwohl","year":"2018","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"21","key":"10.1016\/j.det.2024.02.001_bib21","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1056\/NEJMoa030409","article-title":"Etanercept as monotherapy in patients with psoriasis","volume":"349","author":"Leonardi","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.det.2024.02.001_bib22","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1111\/j.1365-2133.2005.06688.x","article-title":"A\u00a0global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction","volume":"152","author":"Papp","year":"2005","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.det.2024.02.001_bib23","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.jaad.2006.05.027","article-title":"Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study","volume":"55","author":"Gordon","year":"2006","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"8","key":"10.1016\/j.det.2024.02.001_bib24","first-page":"928","article-title":"Long-term safety and efficacy of etanercept in patients with psoriasis: an open-label study","volume":"9","author":"Leonardi","year":"2010","journal-title":"J\u00a0Drugs Dermatol"},{"issue":"2","key":"10.1016\/j.det.2024.02.001_bib25","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/bjd.12654","article-title":"Antidrug antibodies in psoriasis: a systematic review","volume":"170","author":"Hsu","year":"2014","journal-title":"Br J Dermatol"},{"issue":"16","key":"10.1016\/j.det.2024.02.001_bib26","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.2165\/00003495-200464160-00004","article-title":"Managing immunogenic responses to infliximab: treatment implications for patients with Crohn's disease","volume":"64","author":"Han","year":"2004","journal-title":"Drugs"},{"issue":"7","key":"10.1016\/j.det.2024.02.001_bib27","first-page":"1307","article-title":"Management of infusion reactions to infliximab in patients with rheumatoid arthritis or spondyloarthritis: experience from an immunotherapy unit of rheumatology","volume":"33","author":"Lequerr\u00e9","year":"2006","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.det.2024.02.001_bib28","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/00054725-200401000-00011","article-title":"Infliximab infusion reactions: desensitizing ourselves to the danger","volume":"10","author":"Persley","year":"2004","journal-title":"Inflamm Bowel Dis"},{"issue":"6","key":"10.1016\/j.det.2024.02.001_bib29","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1111\/j.1572-0241.2003.07457.x","article-title":"The incidence and management of infusion reactions to infliximab: a large center experience","volume":"98","author":"Cheifetz","year":"2003","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"10.1016\/j.det.2024.02.001_bib30","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.jaad.2010.09.734","article-title":"The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials","volume":"64","author":"Dommasch","year":"2011","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"7","key":"10.1016\/j.det.2024.02.001_bib31","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1002\/art.24632","article-title":"Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry","volume":"60","author":"Tubach","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.det.2024.02.001_bib32","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/BOR.0b013e32835b1366","article-title":"Biologics-induced autoimmune diseases","volume":"25","author":"Perez-Alvarez","year":"2013","journal-title":"Curr Opin Rheumatol"},{"issue":"25","key":"10.1016\/j.det.2024.02.001_bib33","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1161\/01.CIR.0000077913.60364.D2","volume":"107","author":"Chung","year":"2003","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.det.2024.02.001_bib34","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1111\/bjd.12779","article-title":"Melanoma associated with tumour necrosis factor-\u03b1 inhibitors: a Research on Adverse Drug events And Reports (RADAR) project","volume":"170","author":"Nardone","year":"2014","journal-title":"Br J Dermatol"},{"issue":"8","key":"10.1016\/j.det.2024.02.001_bib35","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1002\/ibd.20169","article-title":"Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: a cautionary tale?","volume":"13","author":"Rosh","year":"2007","journal-title":"Inflamm Bowel Dis"},{"issue":"2","key":"10.1016\/j.det.2024.02.001_bib36","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1001\/jamadermatol.2015.3029","article-title":"Risk of Nonmelanoma Skin Cancer Associated With the Use of Immunosuppressant and Biologic Agents in Patients With a History of Autoimmune Disease and Nonmelanoma Skin Cancer","volume":"152","author":"Scott","year":"2016","journal-title":"JAMA Dermatol"},{"issue":"3","key":"10.1016\/j.det.2024.02.001_bib37","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1159\/000235582","article-title":"Predictive factors of eczema-like eruptions among patients without cutaneous psoriasis receiving infliximab: a cohort study of 92 patients","volume":"219","author":"Esmailzadeh","year":"2009","journal-title":"Dermatology"},{"issue":"3","key":"10.1016\/j.det.2024.02.001_bib38","doi-asserted-by":"crossref","first-page":"R666","DOI":"10.1186\/ar1724","article-title":"Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study","volume":"7","author":"Flendrie","year":"2005","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"10.1016\/j.det.2024.02.001_bib39","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.jaad.2020.12.010","article-title":"Paradoxical eruptions to targeted therapies in dermatology: A systematic review and analysis","volume":"86","author":"Murphy","year":"2022","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.det.2024.02.001_bib40","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/S0190-9622(03)70103-0","article-title":"Atopic dermatitis-like eruption precipitated by infliximab","volume":"49","author":"Wright","year":"2003","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2024.02.001_bib41","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2174\/1874312901206010315","article-title":"Anti-Tumor Necrosis Factor-\u03b1 Induced Systemic Lupus Erythematosus","volume":"6","author":"Almoallim","year":"2012","journal-title":"Open Rheumatol J"},{"issue":"8","key":"10.1016\/j.det.2024.02.001_bib42","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1093\/rheumatology\/keu145","article-title":"Alopecia induced by tumour necrosis factor-alpha antagonists: description of 52 cases and disproportionality analysis in a nationwide pharmacovigilance database","volume":"53","author":"B\u00e9n\u00e9","year":"2014","journal-title":"Rheumatology"},{"issue":"5 suppl 1","key":"10.1016\/j.det.2024.02.001_bib43","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1590\/abd1806-4841.20164456","article-title":"Paradoxical psoriasis after the use of anti-TNF in a patient with rheumatoid arthritis","volume":"91","author":"Vasconcellos","year":"2016","journal-title":"An Bras Dermatol"},{"issue":"3","key":"10.1016\/j.det.2024.02.001_bib44","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.jaci.2019.04.029","article-title":"IL-17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis","volume":"144","author":"Krueger","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.det.2024.02.001_bib45","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1084\/jem.20030451","article-title":"Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris","volume":"199","author":"Lee","year":"2004","journal-title":"J\u00a0Exp Med"},{"issue":"6","key":"10.1016\/j.det.2024.02.001_bib46","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.4049\/jimmunol.1800013","article-title":"Discovery of the IL-23\/IL-17 Signaling Pathway and the Treatment of Psoriasis","volume":"201","author":"Hawkes","year":"2018","journal-title":"J\u00a0Immunol"},{"issue":"6","key":"10.1016\/j.det.2024.02.001_bib47","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1111\/j.0022-202X.2004.23448.x","article-title":"A\u00a0phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis","volume":"123","author":"Kauffman","year":"2004","journal-title":"J\u00a0Invest Dermatol"},{"issue":"9625","key":"10.1016\/j.det.2024.02.001_bib48","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)","volume":"371","author":"Leonardi","year":"2008","journal-title":"Lancet"},{"issue":"9625","key":"10.1016\/j.det.2024.02.001_bib49","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)","volume":"371","author":"Papp","year":"2008","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.det.2024.02.001_bib50","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.jaad.2009.11.012","article-title":"Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: rationale for dosing recommendations","volume":"63","author":"Lebwohl","year":"2010","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"12","key":"10.1016\/j.det.2024.02.001_bib51","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1111\/jdv.12046","article-title":"Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study","volume":"27","author":"Kimball","year":"2013","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"7","key":"10.1016\/j.det.2024.02.001_bib52","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/nbt.1903","article-title":"Therapeutic targeting of the IL-12\/23 pathways: generation and characterization of ustekinumab","volume":"29","author":"Benson","year":"2011","journal-title":"Nat Biotechnol"},{"issue":"7","key":"10.1016\/j.det.2024.02.001_bib53","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1111\/jdv.16246","article-title":"Phenotypic switch to eczema in patients receiving biologics for plaque psoriasis: a systematic review","volume":"34","author":"Al-Janabi","year":"2020","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"6","key":"10.1016\/j.det.2024.02.001_bib54","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1111\/1346-8138.14295","article-title":"Exacerbation of atopic dermatitis symptoms by ustekinumab in psoriatic patients with elevated serum immunoglobulin E levels: Report of two cases","volume":"45","author":"Ishiuji","year":"2018","journal-title":"J\u00a0Dermatol"},{"issue":"4","key":"10.1016\/j.det.2024.02.001_bib55","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.alit.2015.06.003","article-title":"Atopic dermatitis exacerbated with ustekinumab in a psoriatic patient with childhood history of atopy","volume":"64","author":"Lis-\u015awi\u0119ty","year":"2015","journal-title":"Allergol Int"},{"issue":"8","key":"10.1016\/j.det.2024.02.001_bib56","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1001\/archdermatol.2012.586","article-title":"Eczematous drug eruption after ustekinumab treatment","volume":"148","author":"Pernet","year":"2012","journal-title":"Arch Dermatol"},{"issue":"5","key":"10.1016\/j.det.2024.02.001_bib57","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.jaad.2011.06.041","article-title":"Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials","volume":"66","author":"Gordon","year":"2012","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.det.2024.02.001_bib58","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1440-0960.2011.00853.x","article-title":"The rapid onset of multiple squamous cell carcinomas in two patients commenced on ustekinumab as treatment of psoriasis","volume":"53","author":"Young","year":"2012","journal-title":"Australas J Dermatol"},{"issue":"10","key":"10.1016\/j.det.2024.02.001_bib59","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1001\/archdermatol.2011.161","article-title":"Reversible posterior leukoencephalopathy syndrome in a patient treated with ustekinumab: case report and review of the literature","volume":"147","author":"Gratton","year":"2011","journal-title":"Arch Dermatol"},{"issue":"4","key":"10.1016\/j.det.2024.02.001_bib60","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/bjd.12214","article-title":"Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up","volume":"168","author":"Papp","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2024.02.001_bib61","unstructured":"Benson J, C.J., Cunningham M, Orlovsky Yevgeniya I, Rauchenberger R, Sweet R. US 9353181 B2, 2012\/06\/15, 2016., Human anti-il-23 antibodies, compositions, methods and uses. US 9353181 B2, 2012\/06\/15, 2016."},{"issue":"1","key":"10.1016\/j.det.2024.02.001_bib62","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2021.1964420","article-title":"A\u00a0non-clinical comparative study of IL-23 antibodies in psoriasis","volume":"13","author":"Zhou","year":"2021","journal-title":"mAbs"},{"issue":"7551","key":"10.1016\/j.det.2024.02.001_bib63","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nature14175","article-title":"Clinical improvement in psoriasis with specific targeting of interleukin-23","volume":"521","author":"Kopp","year":"2015","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.det.2024.02.001_bib64","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1080\/19420862.2015.1032491","article-title":"Selective targeting of the IL23 pathway: Generation and characterization of a novel high-affinity humanized anti-IL23A antibody","volume":"7","author":"Singh","year":"2015","journal-title":"mAbs"},{"issue":"3","key":"10.1016\/j.det.2024.02.001_bib65","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.det.2024.02.001_bib66","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","volume":"76","author":"Reich","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"10091","key":"10.1016\/j.det.2024.02.001_bib67","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/S0140-6736(17)31279-5","article-title":"Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials","volume":"390","author":"Reich","year":"2017","journal-title":"Lancet"},{"issue":"10148","key":"10.1016\/j.det.2024.02.001_bib68","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0140-6736(18)31713-6","article-title":"Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials","volume":"392","author":"Gordon","year":"2018","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.det.2024.02.001_bib69","first-page":"826","article-title":"Long-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two Years","volume":"17","author":"Griffiths","year":"2018","journal-title":"J\u00a0Drugs Dermatol"},{"issue":"6","key":"10.1016\/j.det.2024.02.001_bib70","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1111\/bjd.20595","article-title":"Long-term efficacy and safety of risankizumab for the treatment of moderate-to-severe plaque psoriasis: interim analysis of the LIMMitless open-label extension trial beyond 3 years of follow-up","volume":"185","author":"Papp","year":"2021","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.det.2024.02.001_bib71","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/bjd.18232","article-title":"Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks","volume":"182","author":"Reich","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2024.02.001_bib72","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.670398","article-title":"Adverse Events Associated With Anti-IL-23 Agents: Clinical Evidence and Possible Mechanisms","volume":"12","author":"Ru","year":"2021","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.det.2024.02.001_bib73","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1111\/bjd.17454","article-title":"Safety of guselkumab in patients with moderate-to-severe psoriasis treated through 100 weeks: a pooled analysis from the randomized VOYAGE 1 and VOYAGE 2 studies","volume":"180","author":"Reich","year":"2019","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.det.2024.02.001_bib74","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/ced.14979","article-title":"Anti-interleukin-23 for psoriasis in elderly patients: guselkumab, risankizumab and tildrakizumab in real-world practice","volume":"47","author":"Ruggiero","year":"2022","journal-title":"Clin Exp Dermatol"},{"issue":"4","key":"10.1016\/j.det.2024.02.001_bib75","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis--results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.det.2024.02.001_bib76","doi-asserted-by":"crossref","first-page":"3828","DOI":"10.4049\/jimmunol.1301737","article-title":"Gene expression profiles normalized in psoriatic skin by treatment with brodalumab, a human anti-IL-17 receptor monoclonal antibody","volume":"192","author":"Russell","year":"2014","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.det.2024.02.001_bib77","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.3389\/fimmu.2020.01894","article-title":"Bimekizumab, a Novel Humanized IgG1 Antibody That Neutralizes Both IL-17A and IL-17F","volume":"11","author":"Adams","year":"2020","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.det.2024.02.001_bib78","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s12016-018-8702-3","article-title":"The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis","volume":"55","author":"Blauvelt","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"issue":"4","key":"10.1016\/j.det.2024.02.001_bib79","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1056\/NEJMoa1512711","article-title":"Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis","volume":"375","author":"Gordon","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.det.2024.02.001_bib80","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1111\/jdv.18068","article-title":"Long-term efficacy and safety of brodalumab in moderate-to-severe plaque psoriasis: a post hoc pooled analysis of AMAGINE-2 and -3","volume":"36","author":"Reich","year":"2022","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"2","key":"10.1016\/j.det.2024.02.001_bib81","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/bjd.14493","article-title":"A\u00a0prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis","volume":"175","author":"Papp","year":"2016","journal-title":"Br J Dermatol"},{"issue":"10273","key":"10.1016\/j.det.2024.02.001_bib82","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0140-6736(21)00125-2","article-title":"Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial","volume":"397","author":"Reich","year":"2021","journal-title":"Lancet"},{"issue":"10273","key":"10.1016\/j.det.2024.02.001_bib83","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0140-6736(21)00126-4","article-title":"Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial","volume":"397","author":"Gordon","year":"2021","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.det.2024.02.001_bib84","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1111\/bjd.15706","article-title":"Secukinumab sustains good efficacy and favourable safety in moderate-to-severe psoriasis after up to 3 years of treatment: results from a double-blind extension study","volume":"177","author":"Bissonnette","year":"2017","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.det.2024.02.001_bib85","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.jaad.2020.11.022","article-title":"Long-term efficacy and safety of ixekizumab: A 5-year analysis of the UNCOVER-3 randomized controlled trial","volume":"85","author":"Blauvelt","year":"2021","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.det.2024.02.001_bib86","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1111\/bjd.19132","article-title":"Long-term efficacy and safety of brodalumab in psoriasis through 120 weeks and after withdrawal and retreatment: subgroup analysis of a randomized phase III trial (AMAGINE-1)","volume":"183","author":"Papp","year":"2020","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.det.2024.02.001_bib87","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1093\/bjd\/ljad035","article-title":"Bimekizumab maintenance of response through 3\u00a0years in patients with moderate-to-severe plaque psoriasis: results from the BE BRIGHT open-label extension trial","volume":"188","author":"Strober","year":"2023","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2024.02.001_bib88","article-title":"Adverse events associated with anti-IL-17 agents for psoriasis and psoriatic arthritis: a systematic scoping review","volume":"14","author":"Wang","year":"2023","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.det.2024.02.001_bib89","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1093\/bjd\/ljac021","article-title":"Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial","volume":"188","author":"Tha\u00e7i","year":"2023","journal-title":"Br J Dermatol"},{"issue":"12","key":"10.1016\/j.det.2024.02.001_bib90","doi-asserted-by":"crossref","first-page":"3834","DOI":"10.1093\/rheumatology\/keaa189","article-title":"Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials","volume":"59","author":"Genovese","year":"2020","journal-title":"Rheumatology"},{"issue":"3","key":"10.1016\/j.det.2024.02.001_bib91","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s40257-020-00512-4","article-title":"Malignancy Rates in Brodalumab Clinical Studies for Psoriasis","volume":"21","author":"Gottlieb","year":"2020","journal-title":"Am J Clin Dermatol"},{"issue":"4","key":"10.1016\/j.det.2024.02.001_bib92","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics","volume":"80","author":"Menter","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"9993","key":"10.1016\/j.det.2024.02.001_bib93","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(15)60125-8","article-title":"Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials","volume":"386","author":"Griffiths","year":"2015","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.det.2024.02.001_bib94","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1001\/jamadermatol.2019.1268","article-title":"Morphologic Switch From Psoriasiform to Eczematous Dermatitis After Anti-IL-17 Therapy: A Case Series","volume":"155","author":"Lai","year":"2019","journal-title":"JAMA Dermatol"},{"issue":"3","key":"10.1016\/j.det.2024.02.001_bib95","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/bjd.17779","article-title":"Eczematous eruption during anti-interleukin 17 treatment of psoriasis: an emerging condition","volume":"181","author":"Napolitano","year":"2019","journal-title":"Br J Dermatol"},{"issue":"11","key":"10.1016\/j.det.2024.02.001_bib96","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1038\/ajg.2016.298","article-title":"A\u00a0Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Brodalumab in Patients With Moderate-to-Severe Crohn's Disease","volume":"111","author":"Targan","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.det.2024.02.001_bib97","unstructured":"Registry, E.C.T., A multicenter, subject-blind, investigator-blind, randomized, placebo-controlled study evaluating the efficacy, safety, tolerability, and pharmacokinetics of an IV loading dose followed by SC administration of bimekizumab (UCB4940) in subjects with moderate to severe active ulcerative colitis. 2019."},{"issue":"12","key":"10.1016\/j.det.2024.02.001_bib98","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","article-title":"Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial","volume":"61","author":"Hueber","year":"2012","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.det.2024.02.001_bib99","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jaad.2017.08.024","article-title":"Psychiatric adverse events during treatment with brodalumab: analysis of psoriasis clinical trials","volume":"78","author":"Lebwohl","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"10.1016\/j.det.2024.02.001_bib100","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1001\/jamadermatol.2022.1185","article-title":"Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis: Pooled Results From Phase 2 and Phase 3 Randomized Clinical Trials","volume":"158","author":"Gordon","year":"2022","journal-title":"JAMA Dermatol"},{"issue":"4","key":"10.1016\/j.det.2024.02.001_bib101","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.jaad.2021.09.019","article-title":"Incidence and prevalence of psoriatic arthritis in patients with psoriasis stratified by psoriasis disease severity: Retrospective analysis of an electronic health records database in the United States","volume":"86","author":"Merola","year":"2022","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.det.2024.02.001_bib102","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1136\/annrheumdis-2021-221019","article-title":"Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial","volume":"81","author":"Kristensen","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.det.2024.02.001_bib103","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1093\/rheumatology\/kez684","article-title":"Ixekizumab treatment of biologic-na\u00efve patients with active psoriatic arthritis: 3-year results from a phase III clinical trial (SPIRIT-P1)","volume":"59","author":"Chandran","year":"2020","journal-title":"Rheumatology"},{"issue":"14","key":"10.1016\/j.det.2024.02.001_bib104","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1056\/NEJMoa1412679","article-title":"Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis","volume":"373","author":"Mease","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.det.2024.02.001_bib105","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jaad.2018.06.057","article-title":"Psoriasis: Which therapy for which patient: Psoriasis comorbidities and preferred systemic agents","volume":"80","author":"Kaushik","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"10370","key":"10.1016\/j.det.2024.02.001_bib106","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0140-6736(22)02303-0","article-title":"Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-\u03b1 inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)","volume":"401","author":"Merola","year":"2023","journal-title":"Lancet"},{"issue":"10340","key":"10.1016\/j.det.2024.02.001_bib107","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1016\/S0140-6736(22)00467-6","article-title":"Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials","volume":"399","author":"D'Haens","year":"2022","journal-title":"Lancet"},{"issue":"10340","key":"10.1016\/j.det.2024.02.001_bib108","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/S0140-6736(22)00466-4","article-title":"Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial","volume":"399","author":"Ferrante","year":"2022","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.det.2024.02.001_bib109","doi-asserted-by":"crossref","first-page":"845.e5","DOI":"10.1016\/j.jaad.2017.07.013","article-title":"Risk of malignancy with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment Registry","volume":"77","author":"Fiorentino","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.det.2024.02.001_bib110","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jaad.2016.10.006","article-title":"Malignancy rates in a large cohort of patients with systemically treated psoriasis in a managed care population","volume":"76","author":"Asgari","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.det.2024.02.001_bib111","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1001\/jamadermatol.2020.0024","article-title":"Prevalence, Incidence, and Risk of Cancer in Patients With Psoriasis and Psoriatic Arthritis: A Systematic Review and Meta-analysis","volume":"156","author":"Vaengebjerg","year":"2020","journal-title":"JAMA Dermatol"},{"issue":"6","key":"10.1016\/j.det.2024.02.001_bib112","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s40264-019-00797-3","article-title":"Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn's Disease: An Integrated Analysis of Phase II\/III Clinical Development Programs","volume":"42","author":"Ghosh","year":"2019","journal-title":"Drug Saf"},{"issue":"3","key":"10.1016\/j.det.2024.02.001_bib113","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/bjd.20818","article-title":"Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis","volume":"186","author":"Gordon","year":"2022","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.det.2024.02.001_bib114","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1111\/bjd.20136","article-title":"The risk of malignancy in patients with secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis: analysis of clinical trial and postmarketing surveillance data with up to five years of follow-up","volume":"185","author":"Lebwohl","year":"2021","journal-title":"Br J Dermatol"},{"issue":"10163","key":"10.1016\/j.det.2024.02.001_bib115","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1016\/S0140-6736(18)31946-9","volume":"392","author":"van der Heijde","year":"2018","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.det.2024.02.001_bib116","doi-asserted-by":"crossref","first-page":"88.e5","DOI":"10.1016\/j.jaad.2017.01.037","article-title":"Risk for hepatitis B and C virus reactivation in patients with psoriasis on biologic therapies: A retrospective cohort study and systematic review of the literature","volume":"77","author":"Snast","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.det.2024.02.001_bib117","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1111\/bjd.12461","article-title":"The safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or C","volume":"169","author":"Chiu","year":"2013","journal-title":"Br J Dermatol"},{"issue":"10","key":"10.1016\/j.det.2024.02.001_bib118","doi-asserted-by":"crossref","first-page":"807","DOI":"10.7326\/0003-4819-138-10-200305200-00008","article-title":"Case reports of heart failure after therapy with a tumor necrosis factor antagonist","volume":"138","author":"Kwon","year":"2003","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.det.2024.02.001_bib119","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jaad.2011.07.040","article-title":"Integrated safety analysis: short- and long-term safety profiles of etanercept in patients with psoriasis","volume":"67","author":"Pariser","year":"2012","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.det.2024.02.001_bib120","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1111\/bjd.14964","article-title":"Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta-analysis of randomized controlled trials","volume":"176","author":"Rungapiromnan","year":"2017","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.det.2024.02.001_bib121","first-page":"14","article-title":"The Psoriasis Decision Tree","volume":"14","author":"Monks","year":"2021","journal-title":"J\u00a0Clin Aesthet Dermatol"},{"issue":"6","key":"10.1016\/j.det.2024.02.001_bib122","doi-asserted-by":"crossref","first-page":"e558","DOI":"10.1212\/WNL.0000000000201472","article-title":"Risk of Multiple Sclerosis Among Users of Antitumor Necrosis Factor \u03b1 in 4 Canadian Provinces: A Population-Based Study","volume":"100","author":"Li","year":"2023","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.det.2024.02.001_bib123","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1093\/rheumatology\/kes375","article-title":"Pattern of demyelination occurring during anti-TNF-\u03b1 therapy: a French national survey","volume":"52","author":"Seror","year":"2013","journal-title":"Rheumatology"},{"issue":"8","key":"10.1016\/j.det.2024.02.001_bib124","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1001\/jamaneurol.2020.1162","article-title":"Association Between Tumor Necrosis Factor Inhibitor Exposure and Inflammatory Central Nervous System Events","volume":"77","author":"Kunchok","year":"2020","journal-title":"JAMA Neurol"},{"issue":"7","key":"10.1016\/j.det.2024.02.001_bib125","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1007\/s00415-016-8128-x","article-title":"Activity of secukinumab, an anti-IL-17A antibody, on brain lesions in RRMS: results from a randomized, proof-of-concept study","volume":"263","author":"Havrdov\u00e1","year":"2016","journal-title":"J Neurol"},{"issue":"9","key":"10.1016\/j.det.2024.02.001_bib126","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S1474-4422(08)70173-X","article-title":"Repeated subcutaneous injections of IL12\/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study","volume":"7","author":"Segal","year":"2008","journal-title":"Lancet Neurol"},{"issue":"10","key":"10.1016\/j.det.2024.02.001_bib127","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1080\/14740338.2016.1221923","article-title":"Safety of secukinumab in the treatment of psoriasis","volume":"15","author":"Blauvelt","year":"2016","journal-title":"Expert Opin Drug Saf"},{"issue":"3","key":"10.1016\/j.det.2024.02.001_bib128","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1001\/jamadermatol.2019.4029","article-title":"Comparison of Biologics and Oral Treatments for Plaque Psoriasis: A Meta-analysis","volume":"156","author":"Armstrong","year":"2020","journal-title":"JAMA Dermatol"},{"issue":"2","key":"10.1016\/j.det.2024.02.001_bib129","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1056\/NEJMoa2102388","article-title":"Bimekizumab versus Adalimumab in Plaque Psoriasis","volume":"385","author":"Warren","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.det.2024.02.001_bib130","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa2102383","article-title":"Bimekizumab versus Secukinumab in Plaque Psoriasis","volume":"385","author":"Reich","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.det.2024.02.001_bib131","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.jaad.2021.02.057","article-title":"Comparative safety and benefit-risk profile of biologics and oral treatment for moderate-to-severe plaque psoriasis: A network meta-analysis of clinical trial data","volume":"85","author":"Shear","year":"2021","journal-title":"J\u00a0Am Acad Dermatol"}],"container-title":["Dermatologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863524000135?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863524000135?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T21:39:19Z","timestamp":1716500359000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733863524000135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":131,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S0733863524000135"],"URL":"https:\/\/doi.org\/10.1016\/j.det.2024.02.001","relation":{},"ISSN":["0733-8635"],"issn-type":[{"value":"0733-8635","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biologics for Psoriasis","name":"articletitle","label":"Article Title"},{"value":"Dermatologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.det.2024.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}